Poolbeg’s cytokine release syndrome drug shows potential by John Pinching | Jan 17, 2024 | News | 0 Data supports Poolbeg’s strategic expansion of POLB 001 Read More
Momentum for Poolbeg and CytoReason’s AI collaboration by John Pinching | Jun 29, 2023 | News | 0 Partnership establishes several influenza therapy targets using artificial intelligence Read More
Poolbeg progress oral vaccine programme by John Pinching | Jun 22, 2023 | News | 0 Poolbeg’s platform will possess the capability to generate vaccines for a wide range of diseases Read More
Positive results from Poolbeg Pharma’s human challenge trial by John Pinching | Mar 2, 2023 | News | 0 Candidate POLB 001 demonstrates potential in treating multiple influenza conditions Read More
Poolbeg signs AI deal to advance human challenge data by John Pinching | Mar 24, 2022 | News | 0 Collaboration will focus on AI analysis of flu progression, immune responses and the development of new vaccines Read More